7XC Stock Chart & Stats
€33.40
€0.60(2.36%)
At close: 4:00 PM EST
€33.40
€0.60(2.36%)
Day’s Range― - ―
52-Week Range€26.20 - €38.00
Previous CloseN/A
Volume0.00
Average Volume (3M)7.00
Market Cap
€8.98B
Enterprise Value€8.90K
Total Cash (Recent Filing)€223.21M
Total Debt (Recent Filing)€894.65M
Price to Earnings (P/E)27.5
Beta0.26
Next Earnings
Aug 06, 2026EPS Estimate
0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.57
Shares Outstanding236,240,230
10 Day Avg. Volume5
30 Day Avg. Volume7
Financial Highlights & Ratios
PEG Ratio0.25
Price to Book (P/B)1.82
Price to Sales (P/S)15.45
P/FCF Ratio19.43
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€40.97Price Target Upside22.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.31
Revenue Forecast (FY)€438.53M
Bulls Say, Bears Say
Bulls Say
Cash Generation & FCF QualityHigh and well‑correlated operating and free cash flow provides durable internal funding for dividends and acquisitions, reduces immediate refinancing needs, and underpins earnings quality. Strong cash conversion supports steady distributions and disciplined growth over the next several quarters.
Conservative Balance Sheet & LiquidityLow leverage, ample revolver capacity and an investment‑grade rating materially lower refinancing and covenant risk. This structural liquidity enables continued accretive investing and supports dividend increases while providing a buffer against sector stress over a multi‑quarter horizon.
Repeatable, Accretive Investment ActivitySustained, yield‑accretive deployment indicates scalable origination and underwriting capabilities. Expanding scale and geographic diversification (U.S. SHOP and UK care homes) should support mid‑term FFO/FAD growth if management maintains disciplined underwriting and captures pipeline deals.
Bears Say
Cap‑rate Compression & SHOP CompetitionSustained cap‑rate compression and fierce competition in the SHOP channel reduce prospective acquisition yields, forcing either riskier bids or lower returns. Over multiple quarters this structural pressure can erode accretion from new deals and compress portfolio cash yields.
Loan‑book Accounting ComplexityExpanding financing receivables that resemble sale‑leasebacks increase accounting and disclosure complexity, making it harder to assess core REIT cash flows. Persisting growth here could introduce volatility in reported earnings and investor uncertainty about underlying portfolio economics.
Historical Earnings & Debt Reporting VolatilityMaterial swings in reported debt and prior-year losses signal episodic volatility or one‑offs that complicate trend analysis. Such variability in leverage and earnings disclosure can obscure risk, making long‑term capital planning and investor confidence more fragile through macro or sector stress.
CareTrust REIT News
7XC FAQ
What was CareTrust REIT’s price range in the past 12 months?
CareTrust REIT lowest stock price was €26.20 and its highest was €38.00 in the past 12 months.
What is CareTrust REIT’s market cap?
CareTrust REIT’s market cap is €8.98B.
When is CareTrust REIT’s upcoming earnings report date?
CareTrust REIT’s upcoming earnings report date is Aug 06, 2026 which is in 10 days.
How were CareTrust REIT’s earnings last quarter?
CareTrust REIT released its earnings results on May 07, 2026. The company reported €0.316 earnings per share for the quarter, beating the consensus estimate of €0.311 by €0.005.
Is CareTrust REIT overvalued?
According to Wall Street analysts CareTrust REIT’s price is currently Undervalued.
Does CareTrust REIT pay dividends?
CareTrust REIT does not currently pay dividends.
What is CareTrust REIT’s EPS estimate?
CareTrust REIT’s EPS estimate is 0.32.
How many shares outstanding does CareTrust REIT have?
CareTrust REIT has 236,240,230 shares outstanding.
What happened to CareTrust REIT’s price movement after its last earnings report?
CareTrust REIT reported an EPS of €0.316 in its last earnings report, beating expectations of €0.311. Following the earnings report the stock price went up 4.165%.
Which hedge fund is a major shareholder of CareTrust REIT?
Currently, no hedge funds are holding shares in DE:7XC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CareTrust REIT Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€40.97 (22.67% Upside)
€40.97 (22.67% Upside)
Blogger Sentiment
Bullish
DE:7XC Sentiment 70%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
43.90%
12-Months-Change
Fundamentals
Return on Equity
3.35%
Trailing 12-Months
Asset Growth
34.82%
Trailing 12-Months
Company Description
CareTrust REIT
CareTrust REIT, Inc. operates as a self-managed, publicly traded real estate investment trust. The company specializes in the ownership, acquisition, development, and leasing of various healthcare properties, including skilled nursing facilities, seniors' housing complexes, and other related medical real estate. It maintains a broad, nationwide portfolio of assets, all under long-term net lease agreements with an expanding group of reputable operators. CareTrust REIT is actively pursuing strategic growth across the United States, leveraging both external investments and organic expansion opportunities.
7XC Company Deck
7XC Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: substantial year-to-date investment activity (~$1.1B), double-digit per-share FFO/FAD growth, raised guidance, an investment-grade rating, strong rent coverage, and ample liquidity. The primary headwinds are competitive pressure and cap-rate compression in SHOP and selective pricing pressure on larger SNF deals, as well as modest near-term increases in G&A and accounting complexity around loans. Overall, the positives (accelerating investment activity, upgraded rating, raised guidance, strong earnings and coverage, and healthy liquidity) materially outweigh the challenges described.View all DE:7XC earnings summaries7XC Stock 12 Month Forecast
Average Price Target
€40.97
▲(22.67% Upside)
Technical Analysis
National Health Investors
―
Omega Healthcare
―
Sabra Healthcare REIT
―
Healthcare Realty Trust
―
American Healthcare REIT, Inc.
―